Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2966 | Placebo injection Wiki | 1.00 |
| drug2351 | Mesenchymal stromal cells Wiki | 0.58 |
| drug2916 | Placebo Wiki | 0.04 |
Navigate: Correlations HPO
There is one clinical trial.
This is a first-in-human study to assess the safety, tolerability and pharmacokinetics of escalating single doses of apramycin. This trial will be conducted as a single ascending dose trial in up to 5 sequential dose cohorts (group-comparison). Each cohort will consist of 8 healthy subjects, 6 will receive apramycin and 2 placebo.
Description: Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant vital sign measurement blood pressure. Time: until 2 weeks after dosingDescription: Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant vital sign measurement pulse rate. Time: until 2 weeks after dosingDescription: Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant observation in physical examination. Time: until 2 weeks after dosingDescription: Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant changes in clinical laboratory parameters. Time: until 2 weeks after dosingDescription: ECG parameters include heart rate and PQ, QT, RS. Frequency is defined as number of subjects with clinically significant observations.
Measure: Number of subjects with clinically significant changes in ECG parameters. Time: until 2 weeks after dosingAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports